BioTime Awarded a $4.7 Million Research Grant from the California Institute for Regenerative Medicine Grant to Fund Expansion of BioTime’s ACTCellerate™ Human Embryonic Stem Cell Product Development ...
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT and TASE: BTX) today announced that it has agreed to sell up to $20.7 million of its common shares in a registered direct offering to select ...
BioTime completes expected acquisition of Asterias. Shares move 7% higher as BioTime broadens pipeline. Top management and a promising clinical program make BTX attractive. Shares of BioTime, Inc.
BioTime, Inc.BTX was a big mover last session, as the company saw its shares rise above 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback